Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the day.

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock. VKTX’s Progress With Its Obesity Program Encouraging VK2735 has shown ...